Mahamadou D Camara, Yitian Zhou, Antoine Dara, Mamadou M Tékété, Taís Nóbrega de Sousa, Sékou Sissoko, Laurent Dembélé, Nouhoun Ouologuem, Amadou Hamidou Togo, Mohamed L Alhousseini, Bakary Fofana, Issaka Sagara, Abdoulaye A Djimde, Pedro J Gil, Volker M Lauschke
Dihydroartemisinin-piperaquine is efficacious for the treatment of uncomplicated malaria and its use is increasing globally. Despite the positive results in fighting malaria, inhibition of the Kv11.1 channel (hERG; encoded by the KCNH2 gene) by piperaquine has raised concerns about cardiac safety. Whether genetic factors could modulate the risk of piperaquine-mediated QT prolongations remained unclear. Here, we first profiled the genetic landscape of KCNH2 variability using data from 141,614 individuals. Overall, we found 1,007 exonic variants distributed over the entire gene body, 555 of which were missense...
March 28, 2024: Antimicrobial Agents and Chemotherapy